NEW BRUNSWICK, N.J. / May 14, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th, 2025. Management will participate in a Fireside Chat at 3:20 p.m. Eastern Time.
This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
The audio webcast replay will be available approximately 48 hours after the webcast.
| Last Trade: | US$177.81 |
| Daily Change: | 0.64 0.36 |
| Daily Volume: | 2,456,760 |
| Market Cap: | US$428.520B |
September 02, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
